Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Daver NG, et al. Among authors: visani g. Blood. 2023 Mar 16;141(11):1265-1276. doi: 10.1182/blood.2022016362. Blood. 2023. PMID: 36265087 Free PMC article. Clinical Trial.
Interleukin-9 stimulates the proliferation of human myeloid leukemic cells.
Lemoli RM, Fortuna A, Tafuri A, Fogli M, Amabile M, Grande A, Ricciardi MR, Petrucci MT, Bonsi L, Bagnara G, Visani G, Martinelli G, Ferrari S, Tura S. Lemoli RM, et al. Among authors: visani g. Blood. 1996 May 1;87(9):3852-9. Blood. 1996. PMID: 8611712 Free article.
Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.
Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, Amabile M, Terragna C, Ruggeri D, Piccaluga PP, Isidori A, Malagola M, Baccarani M, Tura S, Martinelli G. Buonamici S, et al. Among authors: visani g. Blood. 2002 Jan 15;99(2):443-9. doi: 10.1182/blood.v99.2.443. Blood. 2002. PMID: 11781223 Free article.
Immunotherapy in Acute Myeloid Leukemia: Where We Stand.
Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A. Isidori A, et al. Among authors: visani g. Front Oncol. 2021 May 10;11:656218. doi: 10.3389/fonc.2021.656218. eCollection 2021. Front Oncol. 2021. PMID: 34041025 Free PMC article. Review.
Novel Agents for Acute Myeloid Leukemia.
Luppi M, Fabbiano F, Visani G, Martinelli G, Venditti A. Luppi M, et al. Among authors: visani g. Cancers (Basel). 2018 Nov 9;10(11):429. doi: 10.3390/cancers10110429. Cancers (Basel). 2018. PMID: 30423907 Free PMC article. Review.
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Candoni A, Papayannidis C, Martinelli G, Simeone E, Gottardi M, Iacobucci I, Gherlinzoni F, Visani G, Baccarani M, Fanin R. Candoni A, et al. Among authors: visani g. Am J Hematol. 2018 May;93(5):655-663. doi: 10.1002/ajh.25057. Epub 2018 Mar 2. Am J Hematol. 2018. PMID: 29396857 Free article. Clinical Trial.
Conditioning regimens in acute myeloid leukemia.
Visani G, Malagola M, Guiducci B, Lucesole M, Loscocco F, Gabucci E, Paolini S, Piccaluga PP, Isidori A. Visani G, et al. Expert Rev Hematol. 2014 Aug;7(4):465-79. doi: 10.1586/17474086.2014.939066. Expert Rev Hematol. 2014. PMID: 25025371 Review.
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.
Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, Cattaneo C, Bonuomo V, Busca A, Ferreri AJM, Bruna R, Petrucci L, Cairoli R, Salvini M, Bertù L, Ladetto M, Pilerci S, Pinto A, Ramadan S, Marchesi F, Cavo M, Arcaini L, Coviello E, Romano A, Musto P, Massaia M, Fracchiolla N, Marchetti M, Scattolin A, Tisi MC, Cuneo A, Della Porta M, Trentin L, Turrini M, Gherlinzoni F, Tafuri A, Galimberti S, Bocchia M, Cardinali V, Cilloni D, Corso A, Armiento D, Rigacci L, La Barbera EO, Gambacorti-Passerini C, Visani G, Vallisa D, Venditti A, Selleri C, Conconi A, Tosi P, Lanza F, Candoni A, Krampera M, Corradini P, Passamonti F, Merli F; ITA-HEMA-COV investigators. Visco C, et al. Among authors: visani g. Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691. Blood Adv. 2022. PMID: 34644385 Free PMC article.
All-trans-retinoic acid and pseudotumor cerebri.
Visani G, Manfroi S, Tosi P, Martinelli G. Visani G, et al. Leuk Lymphoma. 1996 Nov;23(5-6):437-42. doi: 10.3109/10428199609054851. Leuk Lymphoma. 1996. PMID: 9031073 Review.
370 results